Clinical trial · Observational
Intra-Arterial Treatment of Pancreatic Cancer Using the RenovoCath™ RC120 Catheter
A Multi-Center, Post-Marketing, Prospective, Observational Study Following Treatment With Intra-Arterial Delivery of Chemotherapeutic Agents Using the RenovoCath™ RC120 Catheter
NCT02591082CI-TRIAL-00054556completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is an observational study to assess patient survival and clinical outcomes after the RenovoCath™ RC120 catheter is used to deliver chemotherapeutic agents to pancreatic tumors.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Pancreatic Neoplasms | Pancreatic Neoplasm | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| RenovoCath™ R120 Catheter | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Survival
- timeFrame
- 2 Years
- description
- Duration of survival in patients diagnosed with pancreatic cancer who undergo intra-arterial delivery of chemotherapeutic agents to the pancreas
Secondary outcomes (1)
- measure
- Tumor response
- timeFrame
- 6 months
- description
- Time to tumor response in the primary site of application as assessed by imaging.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * 18 years of age * Diagnosed with unresectable or borderline resectable pancreatic adenocarcinoma confirmed by histology or cytology * Without current myelotoxicity and with sufficient health status to undergo a catheterization procedure * Willing to provide informed consent and comply with the required follow-up. Exclusion Criteria: * Have received prior chemotherapy and/or radiation therapy within 14 days prior to the first intra-arterial treatment. * Currently participating in another active drug or device study or registry protocol that would interfere with this study. * Vulnerable populations: prisoners, pregnant or breastfeeding females.
References
Publications (1)
- DERIVEDHatoum H, Rosemurgy A 2nd, Bastidas JA, Zervos E, Muscarella P 2nd, Edil BH, Cynamon J, Johnson DT, Thomas C, Swinson BM, Nordgren A, Vitulli P, Nutting C, Gipson M, Tsobanoudis A, Agah R. Treatment of locally advanced pancreatic cancer using localized trans-arterial micro perfusion of gemcitabine: combined analysis of RR1 and RR2. Oncologist. 2024 Aug 5;29(8):690-698. doi: 10.1093/oncolo/oyae178. PMID 39049803